Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | University of Alabama at BirminghamOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03879577 | Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer | active not recruiting | Phase 2 | 53 | University of ChicagoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04448886 | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | active not recruiting | Phase 2 | 110 | Ana C Garrido-Castro, MDOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT05826964 | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | active not recruiting | Phase 2 | 24 | University of MiamiOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04290793 | Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | active not recruiting | Phase 2 / Phase 3 | 113 | Hebei Medical University Fourth HospitalOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04872985 | Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer | active not recruiting | Phase 2 | 140 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT01196936 | Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors(LDTam) | active not recruiting | Phase 2 | 84 | University of Alabama at BirminghamOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03344965 | Olaparib In Metastatic Breast Cancer | active not recruiting | Phase 2 | 114 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05023967 | Metformin and Nightly Fasting in Women With Early Breast Cancer | active not recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 2 | Jan 5, 2026 | clinicaltrials |
| NCT03090165 | Ribociclib and Bicalutamide in AR+ TNBC | active not recruiting | Phase 1 / Phase 2 | 37 | Kari WisinskiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03393845 | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | active not recruiting | Phase 2 | 47 | Nancy Chan, MDOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04762979 | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | active not recruiting | Phase 2 | 44 | Marina N SharifiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT03285412 | CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer(LEADER) | active not recruiting | Phase 2 | 120 | Massachusetts General HospitalOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02755896 | Trial to Compare Radiation Fibrosis With Five Versus Three Fractions | active not recruiting | Phase 2 | 350 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04538742 | A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer(DB-07) | active not recruiting | Phase 1 / Phase 2 | 245 | AstraZenecaINDUSTRY | 15 | Dec 8, 2025 | clinicaltrials |
| NCT06612203 | Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer(WIN-B) | active not recruiting | Phase 1 / Phase 2 | 76 | MedSIROTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT01898117 | Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer(Triple-B) | active not recruiting | Phase 2 | 304 | The Netherlands Cancer InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT03571633 | Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer(BREASTIMMU02) | active not recruiting | Phase 2 | 90 | Centre Leon BerardOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT)(MARGOT) | active not recruiting | Phase 2 | 174 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT02827877 | Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer | active not recruiting | Phase 2 | 18 | City of Hope Medical CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04561362 | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 329 | BicycleTx LimitedINDUSTRY | 6 | Nov 14, 2025 | clinicaltrials |
| NCT05949021 | OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer | active not recruiting | Phase 2 | 30 | Mridula George, MDOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT00572481 | Axillary Reverse Mapping(ARM) | active not recruiting | Phase 2 | 1,000 | University of ArkansasOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03707340 | A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors | active not recruiting | Phase 2 | 43 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04821141 | Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens | active not recruiting | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04272801 | Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer(POWER) | active not recruiting | Phase 2 | 84 | Shayna Showalter, MDOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04009044 | Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast | active not recruiting | Phase 2 | 156 | Northwestern UniversityOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT01203839 | Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer | active not recruiting | Phase 2 | 110 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02393794 | Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 1 / Phase 2 | 51 | Priyanka SharmaOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02562118 | Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 40 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04520269 | A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) | active not recruiting | Phase 1 / Phase 2 | 74 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04280536 | Phase II Study of FTD/TPI (Lonsurf) in Metastatic Breast Cancers With or Without Prior Exposure to Fluoropyrimidines (LONBRECA) | active not recruiting | Phase 1 / Phase 2 | 86 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT03283384 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.(NEOLBC) | active not recruiting | Phase 2 | 100 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03820063 | Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study(TRAIN-3) | active not recruiting | Phase 2 | 462 | Borstkanker Onderzoek GroepNETWORK | 1 | Sep 19, 2025 | clinicaltrials |
| NCT03515798 | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer(PELICAN) | active not recruiting | Phase 2 | 52 | Institut Paoli-CalmettesOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04759248 | Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer(ATREZZO) | active not recruiting | Phase 2 | 55 | SOLTI Breast Cancer Research GroupOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06599216 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer | active not recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT06198751 | A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer | active not recruiting | Phase 2 | 104 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06224244 | External Hypofractionated Radiotherapy With Simultaneous Integrated Boost in Early Breast Cancer Patients(ESIBIRE) | active not recruiting | Phase 2 | 180 | Regina Elena Cancer InstituteOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT02436993 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | active not recruiting | Phase 2 | 120 | University of California, IrvineOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | active not recruiting | Phase 2 | 13 | University of Illinois at ChicagoOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT03831178 | Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting(DHA-WIN) | active not recruiting | Phase 2 | 76 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06394661 | Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer | active not recruiting | Phase 2 | 109 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 23, 2025 | clinicaltrials |
| NCT02788981 | Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 29 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 23, 2026source: clinicaltrials